ArticleNature communications2019
CD4
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed.
- WT1 peptide vaccines of post-allogeneic HSCT maintenance immunotherapy for pediatric acute leukemias: a phase 2 study.Blood advances · 2026Trial
- Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis.Clinical and translational medicine · 2025Trial
- Trial
- Efficient generation of human cDC1-like cells to detect and enhance tumor-reactive T cells via CD4Cell reports methods · 2026Article
- Beyond oncogenesis: the unexplored benefits of viruses in cancer immunity.Nature reviews. Cancer · 2026Review
- PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Protein-dependent CD4iScience · 2026Article
- VPS33B regulates MHC class II antigen presentation in dendritic cells to drive CD4 T cell immunity.iScience · 2026Article
- Co-delivery of endoplasmic reticulum-targeted photosensitizer and Ido-1 inhibitor potentiates immunotherapeutic efficacy in triple-negative breast cancer.Materials today. Bio · 2026Article
- Stem-like PD-1Journal for immunotherapy of cancer · 2026Article
- Development and Immunogenicity Assessment of a Multi-Epitope Antigen Against Zika Virus: An In Silico and In Vivo Approach.Vaccines · 2025Article
- Histone methyltransferase DOT1L maintains cell state and restricts cytotoxic potential of CD8 T cells.Science advances · 2025Article
- Polio virotherapy provokes MDA5 signaling and CD4Microbiology and molecular biology reviews : MMBR · 2025Review
- Comprehensive analysis of the systemic immune landscape across breast cancer subtypes and disease stages.Immuno-oncology technology · 2025Article
- CD2-CD58 axis orchestrates cytotoxic T lymphocyte function and metabolic crosstalk in breast cancer brain metastasis.Journal of cell communication and signaling · 2025Article
- Prolonged but finite antigen presentation promotes reversible defects of "helpless" memory CD8Immunity · 2025Article
- Recent advances in therapeutic cancer vaccines.Nature reviews. Cancer · 2025Review
- Decoding the immune landscape in Ewing sarcoma pathogenesis: The role of tumor infiltrating immune cells and immune milieu.Journal of bone oncology · 2025Review
- Multi-disciplinary approaches paving the way for clinically effective peptide vaccines for cancer.NPJ vaccines · 2025Review
- Cancer vaccines compensate for the insufficient induction of protective tumor-specific immunity of CD3 bispecific antibody therapy.Journal for immunotherapy of cancer · 2025Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.